Recent News

anita Tweet
@docdhanrajani
Final #ACR2026 post (maybe? 😄)! Huge shoutout to @RheumNow and the incredible team for their phenomenal work in rheumatology education! Can’t believe it took me this long to collaborate with them, but I have a feeling this is the beginning of a long-term relationship! 🙌
anita Tweet
@docdhanrajani
@RheumNow The narrative medicine interactive session at #ACR2026 was well attended and had a lot of interesting exchange of thoughts and ideas. Holistic care of patients, attention to caregiver burnout and ensuring provider well being is the need of the hour in rheumatology.
anita Tweet
@docdhanrajani
@RheumNow 🎉 Celebrated 50 years of #PediatricRheumatology at #ACR2026! Meet the Masters: 3 pioneers reflected on the evolution of our field—from early genetics and DMARDs to biologics—and envisioned the future of precision medicine, novel therapies, and mentorship. What a treat
anita Tweet
@docdhanrajani
@RheumNow #1! 🌍 Global pediatric rheumatology workforce challenges! A survey across 32 countries found 40% lacked in-country training programs. Variable accreditation, limited funding & poor specialty awareness remain key barriers. Abstract 1483. #ACR2026
Adela Castro Tweet
@AdelaCastro222
Is it the treatment or the disease? -Multiple meds can cause SCLE: more widespread, EM,Bullous features. -Dupilumab can cause enthesitis: if severe needs dc of medication -Anti-CD 20 may cause IBD (Crohn’s-Like) Great lecture from @md_chawla on Drug induced syndromes #ACR26 https://t.co/EEQL7QNtWC
Antoni Chan MD (Prof) Tweet
@synovialjoints
ACR26 summary, AI and documentation: errors on all five AI platforms tested against guidelines, and cDAPSA documented in 4.9% of PsA records @rheumnow #ACR26 Abstract#0869 Abstract#1348
Antoni Chan MD (Prof) Tweet
@synovialjoints
ACR26 summary, gut joint axis: replenishing TRBV9 CD8 T cells, a dual targeting antibody, calprotectin for gut inflammation, and outcomes of joint gastroenterology and rheumatology meetings. @rheumnow #ACR26 Abstract#1027 Abstract#2941 Abstract#1336 Abstract#2287
anita Tweet
@docdhanrajani
@RheumNow #2. Abstract 1876. A consensus-driven core outcome set for healthcare transition in adolescents and young adults with JIA identifies 10 outcomes spanning the Quadruple Aim framework: Population health, experience of care, cost of care, provider experience. #ACR2026
Bella Mehta Tweet
@bella_mehta
#ACR26 #2965: AI-generated answers to common pt Qs were rated similarly to rheumatologist-written answers. The highest-value approach, was AI plus rheumatologist review, which improved utility, readability, and completeness. The future may be hybrid, not human versus AI.@RheumNow
anita Tweet
@docdhanrajani
@RheumNow #3. Abstract 0041. Can CAR-T therapy truly “reset” the immune system in lupus? Promising findings show that both patient and donor-derived CAR-T suppress key inflammatory gene signatures in SLE, suggesting a molecular immune reset beyond clinical remission. #ACR26
Antoni Chan MD (Prof) Tweet
@synovialjoints
ACR26 summary, diagnosis and classification: lower sensitivity of the 2025 ASAS SPARTAN criteria in early axSpA, and a 28 month reduction in diagnostic delay with an integrated referral pathway. @rheumnow #ACR26 Abstract#2347 Abstract#2540
Antoni Chan MD (Prof) Tweet
@synovialjoints
Reflection on sequencing: antibody status and patient factors predicted outcome more than mechanism, TNFi cycling was the most common switch in the last 2 decades, and Leeds data suggest some treatment failure may be iatrogenic. @rheumnow #ACR26 Abstract#2284 Abstract#1324
Antoni Chan MD (Prof) Tweet
@synovialjoints
ACR26 summary, pain in axSpA: nociplastic features in 32.5%, fibromyalgia in 9.3%, and early back pain improvement associated with better outcomes at 52 weeks. @rheumnow #ACR26 Abstract#1337 Abstract#1354 Abstract#0347
anita Tweet
@docdhanrajani
@RheumNow #4. Continuing the conversation on unmet needs in cSLE. Abstract 2486. The PLUMM trial highlights barriers to clinical trial enrollment in pediatrics. Strict eligibility criteria, patient preference, logistic and feasibility issues limit participation. #ACR2026
anita Tweet
@docdhanrajani
@RheumNow My top 5 from #ACR2026. #5. Abstract 2484. Addressing unmet needs in cSLE using #CARRA registry data. cSLE patients have significant burden of unmet therapeutic needs with currently approved therapies. Urgent call to expedite regulatory approvals of cSLE therapies!
anita Tweet
@docdhanrajani
@RheumNow Abstract #2483 Pediatric Sjögren’s lacks validated clinical trial endpoints, limiting treatment research. This study developed a prioritized, 8-domain patient-centered endpoint for N-of-1 trials, bridging objective disease activity and lived symptom burden. #ACR26

Video

Podcasts

  • ACR 2026 RheumNow Day 4 Recap
  • ACR 2026 Daily Podcasts - Day4b
  • ACR 2026 Daily Podcasts - Day4a
  • ACR 2026 Daily Podcasts - Day3b
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie November RX Update
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
×